|
 |
SimulectThis page contains recent news articles, when available, and an overview of Simulect but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.La zone de production destinée au Simulect est quasiment prête, à l'exception de quelques aménagements mineurs. La montée en puissance de ce nouveau ... L'Usine Nouvelle More Tysabri Problems; Time for a Biogen-Idec Credibility Check - Oct 30, 2009 ...(TNF)-alpha antagonist Enbrel (Etanercept), the anti-CD52 antibody Campath (alemtuzumab), or the interleukin-2 receptor antibody Simulect (basiliximab). ... BNET Kidney Graft Rejection Lower With Thymoglobulin - Nov 9, 2006 The investigators found that at 12 months the composite endpoint was similar between the two groups, at 50.4% for Thymoglobulin, and 56.2% for Simulect ... MedPage Today … Licenses Exclusive Worldwide Rights to Simulect(R) for the... - Feb 21, 2006 Upon approval for its use in IBD, Cerimon will market Simulect and share ... We hope that Simulect can significantly improve the quality of life for IBD ... RedOrbit … Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for... - Jul 9, 2008 ..."In noninfectious uveitis, we believe Simulect has the potential to ... The lead program is a Phase IIb study in which Simulect(R) (basiliximab) is being ... RedOrbit … Licenses Exclusive Worldwide Rights to Simulect(R) for the... - Feb 21, 2006 Upon approval for its use in IBD, Cerimon will market Simulect and share ... We hope that Simulect can significantly improve the quality of life for IBD ... Pay-Per-View - PR Newswire - HighBeam Research … Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for... - Jul 9, 2008 Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Cerimon Pharmaceuticals Licenses Exclusive Worldwide Rights to … - Feb 24, 2006 Upon approval for its use in IBD, Cerimon will market Simulect and share ... We hope that Simulect can significantly improve the quality of life for IBD ... EndoNurse Cerimon Pharmaceuticals Names Daniel Levitt, MD, Ph.D. Executive Vice... - Jan 8, 2007 Cerimon currently has two drugs in development, Simulect(R) (basiliximab), which is expected to enter Phase 2b studies in early 2007 for moderate-to- severe ... Free with registration - PR Newswire - AccessMyLibrary.com Cerimon Pharmaceuticals Initiates ARREST UC-1, a Global Phase 2b … - Apr 4, 2007 NOTE: Simulect(R) is a registered product of Novartis Pharma AG. CONTACT: Jim Welch, Chief Financial Officer of Cerimon Pharmaceuticals, +1-650-827-4000, ... Free with registration - PR Newswire - AccessMyLibrary.com Cerimon begins Ph II POC trial for eye inflammation disease. - Jul 14, 2008 ..."In non-infectious uveitis, we believe Simulect has the potential to significantly improve the quality of life for patients by reducing adverse events often ... $9.94 - Pharma Marketletter - Alacra Store How drugs are born - Nov 20, 2005 Among the better- known are Gleevec, Exelon, Lamisil, Elidel, Trileptal, Foradil, Zelnorm/Zelmac, Neoral, Simulect, Femara and Zometa. ... Pay-Per-View - Jerusalem Post - ProQuest Archiver Federal officials warn MRIs linked to rare and dangerous skin disease... - Mar 1, 2007 Article: Novartis gets European Union approval to market Simulect for ... Transplant News; November 13, 1998 ; 462 words ...Novartis AG, Basel, Switzerland, ... Pay-Per-View - Transplant News - HighBeam Research In Memoriam.(American Association of Kidney Patients )(In memoriam) |... - Dec 1, 2008 Article: Novartis gets European Union approval to market Simulect for ... Transplant News; November 13, 1998 ; 462 words ...Novartis AG, Basel, Switzerland, ... Pay-Per-View - Transplant News - HighBeam Research ES neleido pratÄ™sti "Novartis" vaistų patentų galiojimo - Apr 22, 2005 ..."Novartis" praÅ¡Ä— pratÄ™sti patento galiojimÄ… dviem vaistams: "Simulect" ... "Simulect" Å veicarijoje buvo įregistruotas 1998 m. balandžio 7 d., ... SekundÄ—.lt Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical … - Oct 2, 2007 Simulect(R) (basiliximab) entered a Phase IIb study for moderate-to-severe steroid-refractory ulcerative colitis in the first quarter of 2007, ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Study Supports Lp-PLA2 as Measured by diaDexus Plac( … - Jan 11, 2005 Acute ... significant difference in the rates of total adverse events (2699 in the Thymoglobulin arm vs ... Simulect arm, p=0.29), serious adverse events ... Pay-Per-View - PR Newswire - HighBeam Research Deal Making: Who's Coming to the Table - Apr 1, 2006 Simulect, a monoclonal antibody, selectively blocks the receptor for interleukin-2 (IL-2). ... Under the deal, Novartis will continue to market Simulect for ... PharmExec.com Cerimon Pharmaceuticals Announces Positive Results from a Phase II … - Sep 11, 2008 The Company has completed a Phase IIb study evaluating Simulect(R) ... Cerimon is also evaluating Simulect in a Phase II study in individuals with ... Genetic Engineering News - Genetic Engineering News (press release) Who's coming to the table: noteworthy license deals and alliances.(Dea... - Apr 1, 2006 Simulect, a monoclonal antibody, selectively blocks the receptor for interleukin-2 (IL-2). ... Under the deal, Novartis will continue to market Simulect for ... Free with registration - Pharmaceutical Executive - AccessMyLibrary.com Press Release: Cerimon Pharmaceuticals Initiates ARREST UC-1, a … - Apr 4, 2007 ...including ulcerative colitis, from Novartis Pharma AG, who continues to market the compound as Simulect(R) in transplantation indications. ... Pay-Per-View - PR Newswire - HighBeam Research Article: Q & A: DR. ARTHUR MATAS, DIRECTOR OF THE RENAL … - Jan 13, 2008 Article: Simulect safe in pediatric renal transplant with ... Obesity, Fitness & Wellness Week; June 12, 2004 ; 700+ words ... ... Simulect appears safe in ... Pay-Per-View - Star Tribune - HighBeam Research Genzyme files marketing applications seeking approval of Mozobil in... - Sep 1, 2008 Novartis AG, Basel, Switzerland, announced a European Union (EU) advisory panel has recommended its new transplant drug Simulect be given approval to be ... Pay-Per-View - Transplant News - HighBeam Research Press Release: Study in Today's New England Journal of Medicine … - Nov 9, 2006 PR Newswire; May 13, 1998 ; 700+ words ... ... basiliximab) for prevention of acute rejection episodes in renal transplant recipients ... that Simulect ... Pay-Per-View - PR Newswire - HighBeam Research Ulcerative Colitis Medications - Ulcerative Colitis Health Information... - Feb 20, 2008 These investigational drugs include adalimumab (Humira), which is approved for Crohn's disease, and rituximab (Rituxan), basiliximab (Simulect), ... New York Times Business notebook - Nov 9, 2006 ...s Thymoglobulin for patients undergoing kidney transplants is more effective than Novartis AG's Simulect in reducing the risk of organ rejection and the ... Boston Globe Press Release: After Conversion to myfortic(R), Two-Thirds of Renal … - Jul 26, 2006 Article: Simulect safe in pediatric renal transplant with ... Obesity, Fitness & Wellness Week; June 12, 2004 ; 700+ words ... ... Simulect appears safe in ... Pay-Per-View - PR Newswire - HighBeam Research Monoclonal Antibody Therapeutics to Fill Vacuum Left by Ineffective … - Jan 25, 2005 There are currently ten products commercially available in Europe including Remicade, Zevalin, Campath, Herceptin, Rituxan, Simulect, Zenapax Synagis, ... Free with registration - PR Newswire Europe - AccessMyLibrary.com Children's Hospital of Pittsburgh recognized for establishing first... - Jun 30, 2006 Article: Novartis Simulect receives EU committee recommendation for use in ... Transplant News; September 24, 2000 ; 700+ words . ... Pay-Per-View - Transplant News - HighBeam Research FDA accepts IND for cancer mAbs - Mar 30, 2005 These include Remicade (Infliximab), Zevalin (Ibritumomab Tiuxetan), Campath (Alemtuzumab), Herceptin (Trastuzumab), Rituxan (rituximab), Simulect ... DrugResearcher.com Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum. - Oct 5, 2007 Simulect(R) (basiliximab)entered a Phase IIb study for moderate-to-severe steroid-refractory ulcerative colitis in the first quarter of 2007, ... Free with registration - PR Newswire - AccessMyLibrary.com Trendspotting: a shift in intellectual property focus - Apr 24, 2006 An example of this includes S. San Francisco, California-based Cerimon Pharmaceuticals' in-licensing of Simulect, an antibody currently being marketed by ... Nature.com GPC Biotech starts trials of cancer antibody - Feb 3, 2005 There are currently ten products commercially available in Europe including Remicade, Zevalin, Campath, Herceptin, Rituxan, Simulect, Zenapax Synagis, ... DrugResearcher.com Excellent Kidney-Transplant Outcomes Seen After Early Steroid … - Jan 18, 2007 Steroid-based-maintenance group (n = 502) -- Induction therapy with basiliximab ( Simulect, Novartis), followed by maintenance therapy with prednisone, ... Medscape BioWorld International Correspondent - May 4, 2005 ...by F. Hoffmann-La Roche Ltd., of Basel, Switzerland, and basiliximab, a chimeric monoclonal antibody marketed as Simulect by Novartis AG, also of Basel. ... BioWorld Online - BioWorld Online Creative Lynx to work on Novartis transplantation brands - Oct 12, 2005 Novartis' current transplantation portfolio includes Myfortic, Neoral and Simulect. Neoral is its biggest selling transplantation product and its fifth ... Pharmafocus Cerimon, Novartis initiate proof of concept study of potential... - Mar 18, 2008 Simulect (basiliximab, Cerimon) is a monoclonal antibody that selectively blocks interleukin-2 receptors, effectively inhibiting the activation of ... OSN SuperSite [医è?¯ç”Ÿç‰©]äº§èƒ½è¿‡å‰©ç«žäº‰è¿‡åº¦ç ”å?‘薄弱创新ä¸?足 - Jul 8, 2005 ...投入，仅2001年～2003年就批准了5ç§?治疗性å?•å…‹éš†æŠ—体，它们分别 是Herceptinã€?Rituxanã€?Simulectã€?Remicadeå’ŒSynagis。其他国家和地区生物制è?¯åŸºæœ¬ä¸Š 处于起æ¥é˜¶æ®µã€‚ ä¸é‡‘在线 Press Release: Cerimon Pharmaceuticals Initiates Phase I Clinical... - Oct 2, 2007 ...initiation of Phase IIb testing for Simulect(R) (basiliximab) in the first quarter," stated Paul Sekhri, President and CEO of Cerimon Pharmaceuticals. ... Pay-Per-View - PR Newswire - HighBeam Research Sodium Mycophenolate/Everolimus Regimen Effective After Calcineurin … - Aug 12, 2008 After induction therapy with basiliximab (Simulect), all patients received CsA, EC-MPS, and corticosteroids for the first 4.5 months post-transplant. ... DG News 器官移æ¤?催çƒè¿‘百亿元的å…?疫抑制剂市场 - Mar 28, 2006 ...诺å?ŽäºŽ2003年在我国市场推出的新型å…?疫抑制剂舒莱（Simulect，或BasiliXimab），2005 年国内销售é¢?也已达到近3000万元。 è¿‘å¹´æ?¥ï¼Œå¦‚å¤?å?ˆÎ±å¹²æ‰°ç´ ã€?抗Tacå?•æŠ—ã€?抗淋巴细胞 ... æ?œç‹? Press Release: Cerimon Pharmaceuticals Names Daniel Levitt, MD, Ph.D … - Jan 8, 2007 Dr. Levitt will direct Cerimon's product development activities and manage the Company's clinical programs for its lead product candidate, Simulect(R), ... Pay-Per-View - PR Newswire - HighBeam Research Other News To Note - Oct 16, 2008 ...that its Thymoglobulin (antithymocyte globulin [rabbit]) resulted in less incidence of acute rejection compared to Simulect (basiliximab, Novartis AG). ... TMC Net Trục trặc của ca ghép gan thứ hai đã được giải quyết - Jun 21, 2006 Trong đó, bệnh nhân bắt buá»™c phải dùng thuốc chống thải ghép Simulect giá 50 triệu đồng/lá»? và thuốc chống siêu vi trùng Acyclovir. ... Dân Trà FDA panel unanimously recommends approval of Thoratec's LVAS as … - Dec 1, 2007 Switzerland, announced a European Union (EU) advisory panel has recommended its new transplant drug Simulect ... to be marketed in the EU. ... Pay-Per-View - Transplant News - HighBeam Research basiliximab Novartis phase change II, Europe (autoimmune disease).( … - Jan 31, 2005 Basel, Switzerland, that a phase II trial is under way in Europe with basiliximab (SIMULECT) in the treatment of autoimmune diseases. ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Press Release: Cerimon Pharmaceuticals to Present at the 2007 BIO … - Oct 5, 2007 Simulect(R) (basiliximab)entered a Phase IIb study for moderate-to-severe steroid-refractory ulcerative colitis in the first quarter of 2007, ... Pay-Per-View - PR Newswire - HighBeam Research Study Shows Neoral(R) Provides Kidney Transplant Patients With... - Aug 7, 2006 Novartis markets the broadest immunosuppressant portfolio in the industry with 4 products (Neoral(R) myfortic(R), Certican(R) and Simulect(R)) and continues ... Medical News Today - Medical News Today (press release) Press Release: Cerimon to Conduct a Proof of Concept Study for … - Mar 10, 2008 ...of concept study for Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, an autoimmune inflammation of the eye's internal structures. ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Cerimon Pharmaceuticals Initiates Phase II/III... - Jan 16, 2008 In April 2007, the Company initiated a Phase IIb study of Simulect(R) (basiliximab) for moderate-to-severe steroid-refractory ulcerative colitis. ... Pay-Per-View - PR Newswire - HighBeam Research First-in-class asthma therapy Xolair® wins prestigious Prix Galien... - Sep 27, 2006 ...countries for the innovative therapies Rimactan®, Parlodel®, Sandimmune®, Sandostatin®, Simulect®, Visudyne®, Glivec®, Zometa® and recently Xolair®. ... webwire.com Cerimon Pharmaceuticals Announces Creation of Scientific Advisory … - Nov 3, 2006 ..."The SAB's knowledge and experience will be an integral component to the success of our clinical and regulatory programs as we move both Simulect and ... Genetic Engineering News - Genetic Engineering News (press release) Cerimon Pharmaceuticals to Present at the BioCentury Future Leaders … - Mar 27, 2006 The Company's lead products are Simulect(R) (basiliximab), a monoclonal antibody which is being advanced towards Phase 2b studies for the treatment of ... RedOrbit ALSO NOTED: Warner Chilcott contraceptive approved; Inspire inks deal... - Feb 20, 2006 Cerimon Pharmaceuticals of South San Francisco has licensed the worldwide rights to Novartis Pharma's Simulect for inflammatory bowel disease. Release ... FierceBiotech Incidence Of Acute Rejection In High-Risk Kidney Transplant Patients ... - Dec 7, 2006 ...had a significantly lower incidence of acute rejection, 15.6 percent, compared to 25.5 percent of patients receiving basiliximab (Simulect). ... Virtual Medical Centre - The Virtual Medical Centre Micromet Presents New Anti-IL-2 Antibody with Unique Mode of Action. - Oct 25, 2006 ...products including monoclonal antibodies (eg, Zenapax(R), Simulect(R)) as well as small molecule inhibitors (eg, rapamycin, cyclosporine, tacrolimus). ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com Early steroid withdrawal after renal transplantation.(Practice Issues... - Jan 1, 2006 A multicenter pilot study of early (4 day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. ... Free with registration - Nephrology Nursing Journal - AccessMyLibrary.com Incidence Of Acute Rejection In High-Risk Kidney Transplant Patients ... - Nov 13, 2006 ...compared to 25.5 percent of patients receiving basiliximab (Simulect®). Anti-thymocyte globulin was even more effective at preventing episodes of acute ... Medical News Today - Medical News Today (press release) Cerimon Pharmaceuticals to Present at the Rodman & Renshaw 8th … - Nov 1, 2006 ...of osteoarthritis pain that will enter Phase 3 studies in 2008 and Simulect, which will enter Phase 2b studies for moderate-to-severe steroid-refractory ... $4.95 - PR Newswire - ECNext Novartis investit près de 22 millions d'euros à ... - Pharmacie, Santé - Jan 17, 2008 Le premier, Simulect, est un immunodépresseur. Le second, un anticorps monoclonal contre l`inflammation, est pour l`instant en essai clinique de phase III. ... L'Usine Nouvelle Press Release: CHOP Plus Zevalin(R) Therapy is Feasible, Tolerable... - Dec 11, 2006 There are currently ten products commercially available in Europe including Remicade, Zevalin, Campath, Herceptin, Rituxan, Simulect, Zenapax Synagis, ... Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: FDA approves Prograf to prevent rejection of heart … - Mar 31, 2006 R- NovoLog- Pfizer- Prograf- Rapamune- Roche- Sanofi-Aventis- Simulect- Squibb- Symlin- TolerRx- Wyeth- Zenepax For more information visit http ... ... Pay-Per-View - M2 Presswire - HighBeam Research Neonatal hemochromatosis: long-term experience with favorable … - Nov 1, 2006 The anti-interleukin-2 receptor antibody basiliximab (Simulect, Novartis Pharma, Basel, Switzerland) was given from 1998 on in 4 patients (25%) in 2 single ... $4.95 - Pediatrics - ECNext Article: Alba Therapeutics Corp.'s newest drug trial will test pet... - Oct 31, 2006 Simulect for injection in inflammatory bowel disease, while Novartis will continue to ... The Daily Record (Baltimore). Article: Latest round of loans ... Pay-Per-View - Daily Record - HighBeam Research Press Release: Cerimon Pharmaceuticals to Present at the BioCentury … - Mar 27, 2006 The Company's lead products are Simulect(R) (basiliximab), a monoclonal antibody which is being advanced towards Phase 2b studies for the treatment of ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Cerimon Pharmaceuticals to Present at the Rodman & … - Nov 1, 2006 ...of osteoarthritis pain that will enter Phase 3 studies in 2008 and Simulect, which will enter Phase 2b studies for moderate-to-severe steroid-refractory ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Cerimon Pharmaceuticals Names James Welch as Chief … - Jun 6, 2006 Cerimon's lead products are Simulect(R) (basiliximab), a monoclonal antibody, which is being advanced towards Phase 2b studies for the treatment of ... Pay-Per-View - PR Newswire - HighBeam Research |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |